Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab ... time a medicine has shown a clinical benefit in basal cell carcinoma patients who have progressed or are ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Cemiplimab (Libtayo, Regeneron Pharmaceuticals ... It also is approved for treatment of certain patients with basal cell carcinoma or non-small cell lung cancer. Adjuvant cemiplimab prolonged ...

Libtayo has been approved by regulatory authorities in more than 30 countries in one or more indications, including for certain adult patients with advanced basal cell carcinoma (BCC), advanced CSCC, ...

Beyond CSCC, Libtayo is authorised to treat basal cell carcinoma, the most common type of skin cancer, as well as non-small cell lung cancer (NSCLC). Regeneron recently presented five-years results ...

Danés, principal investigator of the Cancer and Stem Cell Biology Lab at the Champalimaud Foundation, in Lisbon, has shown ...

Basal cell carcinoma (BCC) is an epithelial tumour of the skin. It seldom metastasizes, but has the potential for local invasion and destruction. It usually occurs as one or several small pearly ...